angelica peebles has the details. >> yeah, melissa. disappointing day here for abbvie. drug failed to show a significant difference compared to placebo in two phase two trials. now, there's a couple things going on here. first, the drug didn't perform as well as it was supposed to, and also people who were in the placebo group did better than we expected them to. either way, this is a big disappoint, especially because the company went out and spent $9 billion to acquire this drug through its acquisition of cerevel. on the other hand, this is a big boon for bristol myers squibb. they have a drug that just got approved in september, and the thinking was that they would have a little bit of a head start and that ultimately they would face competition, but now, it looks like they will be there alone with this new type of schizophrenia drug, the first of its kind in decades. the first new innovation that we've seen in this space, so, a really big day for these two companies, melissa. >> and it really -- it value dates bristol myers' fpurchase, and throws into question some